Hyperoside

Hyperoside

1. Identity and Chemical Characterization

1.1 Nomenclature

Quercetin-3-O-β-D-galactopyranoside, known as hyperoside, is a flavonol glycoside. The compound is also referred to in the scientific literature as hyperin, quercetin-3-galactoside, and quercetin 3-O-β-D-galactoside. It is chemically known as quercetin-3-O-β-D-galactopyranoside, with the molecular formula C₂₁H₂₀O₁₂ and appears as a yellow solid at room temperature.

1.2 Chemical Structure

Hyperoside predominantly exists in nature as a glycosylated flavonoid. Specifically, it consists of the natural flavonoid quercetin, which is linked to galactose via a β-glycosidic bond. Its molecular formula is C₂₁H₂₀O₁₂, which corresponds to a molecular weight of 464.3763. Notably, the multiple hydroxyl functional groups distributed across its A and B rings (with the C ring primarily involved in forming glycosidic bonds) confer potent antioxidant, anti-inflammatory, and anti-tumor effects. These biological activities are mediated through the scavenging of reactive oxygen species (ROS) and the regulation of cell signaling pathways.

Hyperoside, also known as quercetin 3-O-beta-D-galactopyranoside, is a yellow solid, and its aglycone is quercetin. Its antioxidant activity may be related to the hydroxyl groups on the A and B rings and the glycosides linked to the C ring, whereas its analgesic effect may be related to 3-galactopyranoside.

1.3 Botanical Sources and Natural Distribution

Hyperoside is a natural flavonol glycoside found in various plants, such as Crataegus pinnatifida Bge, Forsythia suspensa, and Cuscuta chinensis Lam. It is a flavonol glycoside mainly found in plants of the genera Hypericum and Crataegus, and also detected in many plant species such as Abelmoschus manihot, Ribes nigrum, Rosa rugosa, Agrostis stolonifera, Apocynum venetum, and Nelumbo nucifera.

Hyperoside is widely distributed across various plant families, including Hypericaceae, Rosaceae, Polygonaceae, and others such as Erythrinaceae, Labiatae, and Leguminosae. Key source plants include Hypericum monogynum in Hypericaceae, Crataegus pinnatifida in Rosaceae, and Polygonum aviculare in Polygonaceae. Hyperoside, a flavonoid compound, is a polyphenolic substance found abundantly in various parts of plants, including flowers, leaves, and fruits.

In Hypericum perforatum (St. John's Wort), hyperoside is one of a wide range of co-occurring flavonoids. The most common St. John's Wort preparations used are hydroalcoholic extracts of the aerial portion of the plant, which contain at least ten different kinds of biochemical compounds: flavonoids (including rutin, hyperoside, quercetin, quercitrin), naphtodianthrones (including hypericin and pseudohypericin), acylphloroglucinols (including hyperforin and adhyperforin), proanthocyanidins, procyanidines, tannins, essential oil, amino acids, phenylpropanes, xanthones and other hydrosoluble compounds.

Among hawthorn species, Crataegus monogyna is one of the most common species used in traditional medicine for the treatment of many anti-inflammatory diseases, and the entire plant, including the leaves, flowers, and fruits, is used medicinally. Hyperoside was the predominant phenolic compound in leaf extracts of three Potentilla species by RP-HPLC assay.

1.4 Preparation, Extraction, and Commercial Forms

Hyperoside is obtained from plants and chemical synthesis. In plants, it is most efficiently extracted from aerial parts—leaves, flowers, and stems. Almost all metabolites are more accumulated in the leaves than in the stems. Extraction solvents show species-specific differences, with ethanol (EtOH) being more suitable for the extraction of hypericin, quercetin, quercitrin, and hyperoside.

Hyperoside occurs in commercial preparations primarily as a component of standardized plant extracts, most notably hawthorn (Crataegus) berry extract and St. John's Wort (Hypericum perforatum) extract. Modern application forms such as dragees, tablets, and capsules are frequently used, but still the traditional water infusion from herbal tea is prepared for therapeutic purposes. As a pure compound, hyperoside is available as a reference standard and as an isolated phytochemical for research. Researchers have fabricated zein–tea polyphenol–pectin ternary complex nanoparticles and zein–pectin composite nanoparticles as effective delivery systems for hyperoside. Such systems greatly improve the bioavailability of hyperoside.

2. Traditional and Historical Use

2.1 European and Greco-Roman Traditions

The history of hyperoside as an identified molecule is relatively recent; however, the plants that contain it have long medicinal histories. From the rich diversity of medicinal plants in herbal and homeopathic remedies, St. John's Wort is one of the oldest with a history of more than 2000 years. Historical information dating back to 400 BC tells the story of St. John's Wort and its medicinal and spiritual evolution: the ancient Greeks and Romans noted the medical use of SJW. These uses centered on mood disorders, wound healing, and pain—conditions now understood to be partly attributable to flavonoid constituents, including hyperoside.

The use of St. John's Wort, another potent source of hyperoside, dates back to ancient Greece, where it was employed to alleviate nervous disorders and as a mood enhancer.

2.2 Traditional Chinese Medicine (TCM)

Hypericum perforatum L. has a long history as a traditional Chinese medicine, which was traditionally used for the treatment of emotional distress, cardiothoracic depression, and acute mastitis. It was listed in the Chinese Pharmacopoeia as a Chinese herbal medicine, traditionally used for the treatment of emotional distress, cardiothoracic depression, and acute mastitis.

Hyperoside can also be extracted from Crataegus pinnatifida Bunge (genus Crataegus pinnatifida Bunge, family Rosaceae), another traditional Chinese medicine that traditionally prevented and treated heart disease in China. Historically, hyperoside-containing botanicals were utilized to support cardiovascular health, with hawthorn berries being a prime example. Folk remedies often prescribed hawthorn extracts for heart conditions, hypertension, and to enhance overall vitality.

2.3 Discovery and Isolation as a Pure Compound

Since 1960, hyperoside has been isolated from red osier dogwood (Cornus stolonifera Michx.). With the further study of natural medicinal chemistry, many natural drugs have been found to contain flavonoids, and hyperoside is one of the most important components. Its isolation as a discrete molecule allowed researchers to begin systematically characterizing its chemistry and pharmacological properties, a body of work that accelerated notably in the 2000s and 2010s.

3. Key Constituents, Active Compounds, and Mechanisms of Action

3.1 Structure–Activity Relationships

Hyperoside itself is the bioactive entity under study; its parent aglycone is quercetin, one of the most widely studied natural flavonoids. The galactose moiety at the 3-position distinguishes hyperoside from closely related compounds such as rutin (quercetin-3-O-rutinoside) and isoquercitrin (quercetin-3-O-glucoside). The unique chemical structure of hyperoside underpins its diverse biological functions. Notably, the multiple hydroxyl functional groups distributed across its A and B rings confer potent antioxidant, anti-inflammatory, and anti-tumor effects.

3.2 Antioxidant Mechanisms

Hyperoside can be regarded as a common nutrient with properties that include antioxidant, anti-aging, anti-inflammatory, anti-viral, vascular protective, and cancer-preventive effects. Hyperoside possesses antioxidant activity. Wang Mengyu reported that the antioxidant activity of hyperoside is related to the 3-position hydroxyl group of hyperoside. Its multiple hydroxyl groups enable it to donate hydrogen atoms to reactive oxygen species (ROS), neutralizing them directly. Additionally, hyperoside exerts its anti-cancer and brain-, nerve- and kidney-protective functions through the phosphatidylinositol-3-kinase (PI3K)/protein kinase B (AKT) and nuclear factor E2-related factor 2 (Nrf2)/haem oxygenase-1 (HO-1) pathways.

3.3 Anti-Inflammatory Mechanisms

Hyperoside reduces vascular inflammation by inhibiting HMGB1-mediated signaling pathways. The anti-inflammatory activity of hyperoside in mouse peritoneal macrophages can be explained by its ability to inhibit NF-κB activation, suggesting that it plays an essential role in the control of inflammation. Studies have shown that hyperoside can improve intestinal inflammation by inhibiting inflammation and apoptosis through the Nrf2 signaling pathway. In addition, hyperoside was able to stabilize peroxisome proliferator-activated receptor (PPAR)-γ levels by modulating E3 ligase ring finger protein 1 (MKRN1) to alleviate intestinal inflammation, and restores the cellular Th17/Treg immune balance to protect against colitis.

3.4 Cardioprotective Mechanisms

Hyperoside significantly reduces proteolytic calpain activity through the upregulation of its endogenous inhibitor calpastatin, which protects critical proteins like sarco-endoplasmic reticulum Ca²⁺ ATPase-2a and cardiac troponin I from degradation. This preservation of proteins helps maintain intracellular Ca²⁺ homeostasis and myocyte contraction strength. Both in vivo and in vitro experiments showed that hyperoside could increase phosphorylated JAK2 and STAT3, indicating that hyperoside could play a cardioprotective role by activating the JAK2/STAT3 signaling pathway.

3.5 Anticancer Mechanisms

As a flavonoid, hyperoside can exert significant effects on cancer cells through multiple mechanisms. It not only inhibits tumor cell proliferation but also induces apoptosis in these cells. Furthermore, hyperoside influences tumor cell growth and migration by modulating relevant signaling pathways, and it enhances the sensitivity of tumor cells to certain chemotherapy drugs. In studies of breast cancer cell lines, CCK-8 and wound healing assays showed that the viability and migration capability of MCF-7 and 4T1 cells were inhibited by hyperoside, while apoptosis of cells was increased. Analysis showed decreased levels of Bcl-2 and XIAP, and increased levels of Bax and cleaved caspase-3.

3.6 Antidepressant and Neurotrophic Mechanisms

Hyperoside, a natural flavonol, is commonly referred to as 3-O-galactoside of quercetin. Multiple mechanisms have been proposed to explain its antidepressant effects. Haas et al. (2011) suggest hyperoside activates D2 dopamine receptors, potentially contributing to its efficacy. Song et al. (2022) reported a symptom-relieving effect of hyperoside on CUMS (chronic unpredictable mild stress) challenged mice, finding that hyperoside could exert an anti-depressant effect by inhibiting the NLRP1 inflammasome through the CXCL1/CXCR2/BDNF signaling pathway. Hyperoside was reported to exert antidepressant activity in rodents after acute treatment, and this activity might be influenced by the monoaminergic system and the upregulation of the brain-derived neurotrophic factor (BDNF) level.

3.7 Neuroprotective Mechanisms

In models of Parkinson's disease pathology, hyperoside treatment activated the nuclear erythroid 2-related factor 2 (Nrf2), an upstream molecule of heme oxygenase-1 (HO-1). Hyperoside also induced the expression of HO-1, an antioxidant response gene. Remarkably, the neuroprotective effects of hyperoside were weakened by an Nrf2 small interfering RNA, indicating the vital role of HO-1. Overall, hyperoside, via the induction of Nrf2-dependent HO-1 activation, suppresses neuronal death caused by 6-OHDA-induced oxidative stress.

In Alzheimer's disease models, a blood-brain barrier crossing flavonol glycoside hyperoside was identified with anti-Aβ aggregation, BACE inhibitory, and neuroprotective effect in cellular or APP/PSEN1 double transgenic Alzheimer's disease mice models. Pharmacokinetic data confirmed that intranasal administration of hyperoside resulted in higher bioavailability in mice brain, and further in vivo studies revealed that it improved motor deficit, spatial memory, and learning ability of APP/PSEN1 mice with reducing level of Aβ plaques and GFAP in the cortex and hippocampus.

4. Scientific Evidence by Area of Use

4.1 Cardiovascular and Cardioprotective Effects

Hyperoside, a flavonoid glycoside, is recognized for its cardioprotective properties on ischemic cardiomyocytes. However, the detailed mechanisms through which hyperoside confers these benefits remain insufficiently understood. The preponderance of evidence derives from preclinical (animal and cell-based) investigations.

Previous studies have verified that preconditioning with hyperoside inhibits ischemia/reperfusion (I/R)-induced injury in isolated rat hearts, though the mechanisms of its protecting effects on hypoxia/reoxygenation injury remain under investigation. Echocardiographic and histological measurements demonstrated that hyperoside treatment improved cardiac function and ameliorated myocardial hypertrophy and fibrinogen deposition after myocardial infarction.

Hyperoside displayed angiogenic effects, promoting tube formation, migration, and proliferation of endothelial cells. This angiogenesis resulted in greater arteriole and vessel density within the infarcted myocardium and was linked to increased expression of proangiogenic factors, such as von Willebrand factor, angiopoietin-1, and fibroblast growth factor 2.

Hyperoside has a wide range of pharmacological effects, including anti-inflammatory, antispasmodic, diuretic, hypotensive, cholesterol-lowering, protein assimilation and cardio-cerebrovascular protection.

Evidence strength: Cardiovascular evidence is currently preclinical only—restricted to animal models and cell culture systems. No published randomized controlled trials (RCTs) in human populations have tested hyperoside as an isolated compound for cardiovascular endpoints.

4.2 Anti-Inflammatory and Immunomodulatory Effects

Medical research has found that hyperoside possesses a broad spectrum of biological activities, including anticancer, anti-inflammatory, antibacterial, antiviral, antidepressant, and organ protective effects. These pharmacological properties lay the foundation for its use in treating multiple diseases, such as sepsis, arthritis, colitis, diabetic nephropathy, myocardial ischemia-reperfusion, pulmonary fibrosis, and cancers.

In arthritis models, hyperoside has been reported to exert anti-inflammatory and anti-arthritic effects in LPS-stimulated human fibroblast-like synoviocytes in vitro and in mice with collagen-induced arthritis. In hepatic fibrosis, hyperoside induced apoptosis in LX-2 cells and decreased levels of α-smooth muscle actin (α-SMA), type I collagen, and intracellular reactive oxygen species (ROS). Remarkably, hyperoside also inhibited the DNA-binding activity of the transcription factor NF-κB and altered expression levels of NF-κB-regulated genes related to apoptosis, including proapoptotic genes Bcl-Xs, DR4, Fas, and FasL and anti-apoptotic genes A20, c-IAP1, Bcl-XL, and RIP1.

Evidence strength: Anti-inflammatory evidence is predominantly in vitro and in animal models. Clinical (human) studies isolating hyperoside's anti-inflammatory contribution are not yet available.

4.3 Anticancer Effects

The biofunctions of hyperoside were mainly involved in antioxidants, hypoglycemic, anti-cancer, anti-inflammatory, and cardiovascular effects. Previous studies have shown that hyperoside can help with the amelioration of lung cancer, pancreatic cancer, prostate cancer, and colon cancer. In breast cancer cell and animal studies, different concentrations of hyperoside were used to explore its therapeutic potential in both breast cancer cells and subcutaneous homotransplant mouse model. CCK-8 and wound healing assays showed that the viability and migration capability of MCF-7 and 4T1 cells were inhibited by hyperoside, while apoptosis of cells was increased.

Hyperoside has shown remarkable potential in cancer therapy by targeting multiple mechanisms; it induces apoptosis, inhibits proliferation, blocks angiogenesis, and reduces the metastatic potential of cancer cells. Furthermore, hyperoside enhances the sensitivity of cancer cells to chemotherapy by modulating key signaling pathways.

Evidence strength: Anticancer evidence for hyperoside is entirely preclinical (in vitro cell models and animal xenograft models). No human clinical trials have been conducted on hyperoside as an isolated anticancer agent.

4.4 Neurological: Depression and Mood

Hyperoside is the primary active component of Hypericum perforatum (HP), a medicinal plant that has been utilized for centuries and is widely recognized as an effective treatment for mild to moderate depression. HP is often considered the only herbal alternative to traditional synthetic antidepressants.

Preclinical work in rodents has investigated hyperoside as an isolated molecule. Researchers investigated the antidepressant, anxiolytic, and procognitive effects of hyperoside in mice after acute and prolonged treatment (14 days). Both polyphenols (hyperoside and protocatechuic acid) induced an anxiogenic-like effect after acute treatment, whereas an anxiolytic effect occurred after repetitive administration. Compared to traditional antidepressants targeting specific neurotransmitters, hyperoside appears to act through multiple mechanisms, potentially offering a broader therapeutic approach for depression. Further research elucidating the relative contributions of each mechanism could reveal hyperoside's potential for addressing different subtypes of depression.

Evidence strength: Antidepressant effects of hyperoside as an isolated compound have been demonstrated only in preclinical (rodent) models. Clinical trials on standardized Hypericum perforatum extracts (which contain hyperoside alongside many other constituents, including hyperforin) have demonstrated efficacy for mild-to-moderate depression, but the contribution of hyperoside specifically cannot be isolated from these multi-compound trials.

4.5 Neurological: Alzheimer's Disease and Parkinson's Disease

Researchers systematically assessed the neuroprotective potential of hyperoside in in vivo and in vitro models of Alzheimer's disease (AD) and Parkinson's disease (PD). Findings indicated that hyperoside can mitigate, intervene in, and treat AD and PD animal models and associated cells through various mechanisms, including anti-oxidative, anti-inflammatory, anti-apoptotic, anti-Aβ aggregation, and cholinesterase inhibitory activities. Hyperoside potentially exerts anti-AD and anti-PD effects through diverse mechanisms, making it a promising candidate for therapeutic intervention in both AD and PD.

In a study using APP/PS1 transgenic Alzheimer's disease mice, intranasal administration of hyperoside resulted in higher bioavailability in mice brain, and in vivo studies revealed improved motor deficit, spatial memory, and learning ability with reduced Aβ plaque levels in the cortex and hippocampus. Bioinformatics, computational docking, and in vitro assay results suggested that hyperoside binds to Aβ and interacted with ryanodine receptors, then regulated cellular apoptosis via the endoplasmic reticulum-mitochondrial calcium (Ca²⁺) signaling pathway. It was confirmed that hyperoside increased Bcl2, decreased Bax and cyto-c protein levels, and ameliorated neuronal cell death in both in vitro and in vivo models.

Hyperoside has exhibited prominent biological activities against a variety of diseases including cancer, myocardial ischemia, stroke, depression, Alzheimer's disease, and Parkinson's disease.

Evidence strength: Evidence for hyperoside in neurodegenerative disease contexts is preclinical. The systematic review by Deng et al. (2024) consolidated 17 included preclinical studies, confirming that all current evidence derives from animal and cell-based models, not human trials.

4.6 Oxidative Stress and Organ Protection

Hyperoside can prevent age-related macular degeneration and protect against diabetic retinopathy. Hyperoside can also protect the pancreas, fight fatigue, and enhance NK cell proliferation. Its pharmacologic effects include preventing cancer and protecting the brain, neurons, heart, kidneys, lung, blood vessels, bones, joints, and liver, among others. These claims originate from animal and in vitro studies. Beyond neoplastic diseases, hyperoside also presents promising therapeutic applications in managing non-cancerous conditions such as diabetes, Alzheimer's disease, and pulmonary fibrosis.

Evidence strength: Organ-protective effects are supported by preclinical data only. No published human interventional data exist for hyperoside as a standalone compound in these areas.

4.7 Analgesic Effects

Intragastric administration of 100 mg/kg hyperoside in rats significantly reverses the up-regulation of N-methyl-D-aspartic acid (NMDA) receptor containing NR2B in the midbrain periaqueductal grey and shows analgesic activity against continuous inflammatory stimulation in mice.

Evidence strength: Analgesic effects have been studied only in rodent models; no human clinical data are available.

5. Body Systems and Health Areas Associated with Hyperoside

• Cardiovascular system: Hyperoside extracted from Hypericum perforatum L. has been affirmed to exert therapeutic effects on cardiovascular diseases. Areas of investigation include myocardial ischemia-reperfusion injury, heart failure, and vascular inflammation.
• Central nervous system: Hyperoside exhibits a multitude of biological functions including anti-inflammatory, antidepressant, antioxidative, vascular protective effects, and neuroprotective effects.
• Oncology: The anticancer properties of hyperoside are intricately linked to various biological pathways and their associated mechanisms. As a flavonoid, hyperoside can exert significant effects on cancer cells through multiple mechanisms.
• Musculoskeletal/Immune: Preclinical studies implicate hyperoside in arthritis and colitis management via anti-inflammatory and immunomodulatory mechanisms.
• Renal system: Pharmacokinetic analysis of hyperoside has revealed that it mainly accumulates in the kidney, and preclinical work has investigated its role in diabetic nephropathy.
• Hepatic system: Hyperoside has been studied preclinically for hepatic fibrosis via induction of hepatic stellate cell apoptosis.
• Ocular system: Hyperoside can prevent age-related macular degeneration and protect against diabetic retinopathy.

6. Pharmacokinetics and Bioavailability

6.1 Absorption and Oral Bioavailability

Following intragastric administration of hyperoside to rats, researchers observed a half-life of approximately 4 hours and an absolute bioavailability of 26%. This finding suggests that hyperoside could be developed into oral formulations for clinically relevant applications.

Studies have shown that the bioavailability of orally administered hyperoside is lower than that of intraperitoneally injected hyperoside, which may be related to the first-pass metabolism of hyperoside and the physical properties of flavonoids (hydrophobicity).

The drug-time curve after oral administration of hyperoside in rats shows bimodal absorption. This phenomenon may be related to hepato-enteric circulation or absorption by dual parts of the intestine, though these conjectures have not been confirmed by researchers.

6.2 Distribution, Metabolism, and Excretion

The metabolic process of hyperoside is relatively complex and predominantly occurs in the liver, where the enzyme system significantly influences the metabolism of hyperoside. Common metabolic pathways include hydroxylation and glycosylation. Notably, hyperoside is primarily excreted through urine. While there is currently insufficient direct evidence to demonstrate the impact of renal health on the excretion profile of hyperoside, its accumulation in the kidneys underscores the necessity for further investigation into its potential relationship with renal function.

Pharmacokinetic analysis of hyperoside has revealed that it mainly accumulates in the kidney. The absolute bioavailability was 26%, demonstrating that hyperoside could be made into an oral preparation for clinical application. In one study, the half-life of intravenous administration of hyperoside was 264.96 ± 145.80 min as detected with LC/MS.

At present, few studies have explored the pharmacokinetics, especially the excretion, of hyperoside. Novel nanotechnology-based delivery platforms, including nanoparticle encapsulation systems, have been investigated to improve systemic bioavailability.

7. Dosage Forms and Dosages Reported in Studies

Human clinical dosage data for hyperoside as an isolated compound are not yet established, as no registered clinical trials on isolated hyperoside in human populations have been published to date. Dosage information available in the literature refers to experimental animal studies, preclinical pharmacokinetic work, and dosages used in cell-based research. The following are reported as they appear in the cited sources:

• Intragastric administration of 100 mg/kg hyperoside in rats significantly reverses the up-regulation of NMDA receptor NR2B in the midbrain periaqueductal grey and shows analgesic activity against continuous inflammatory stimulation in mice.
• Hyperoside post-conditioning at 18–36 mg/kg/day for 14 days enhanced autophagy to inhibit NLRP1-mediated inflammation in the LAD-ligation model.
• In an in vitro hepatic stellate cell study, cells were treated with different concentrations of hyperoside: 0, 0.125, 0.25, 0.5, 1.0, and 2.0 mM/L.

As an ingredient in plant-based preparations (e.g., St. John's Wort extract, hawthorn extract), hyperoside is not typically dosed as an isolated entity in clinical settings; formulations are standardized to marker compounds such as hypericins (in St. John's Wort) or oligomeric proanthocyanidins (in hawthorn). In view of its notable bioactivities and pharmacological effects, hyperoside is considered to possess a promising application prospect in the food and medicinal industry.

8. Safety Considerations

8.1 Acute Toxicity

The acute toxicity of hyperoside is relatively low. Specifically, the oral median lethal dose (LD50) in mice exceeds 5,000 mg/kg, which corresponds to an approximate human dose of 549.5 mg/kg.

Studies on the toxicity of hyperoside are very few. So far, only one team has studied the toxicity of hyperoside, and only animals were used in their studies. An acute toxicity test of hyperoside showed that its LD50 > 5000 mg/kg. A bacterial reverse mutation assay (Ames test) indicated that hyperoside has no genetic toxicity.

8.2 Reproductive and Developmental Toxicity

An experiment on rat embryo and foetal developmental showed that this compound exerts negligible effects on pregnant rats but slows down the growth of foetal rats. This finding indicates a potential concern for foetal development that warrants further investigation before use can be considered safe during pregnancy.

8.3 Renal Accumulation

Pharmacokinetic analysis of hyperoside has revealed that it mainly accumulates in the kidney. However, long-term application of high-dose hyperoside should be avoided in clinical practice because of its renal toxicity. This renal accumulation represents the most clearly documented safety concern specific to hyperoside.

8.4 General Toxicity Profile

Hyperoside has exhibited prominent biological activities against a variety of diseases and has very low toxicity in the effective dose range. Nevertheless, the overall toxicity database for hyperoside is extremely limited: studies on the toxicity of hyperoside are very few, and so far only one team has studied the toxicity of hyperoside, and only animals were used in their studies. This represents a major gap in the evidence base.

8.5 Drug Interactions: Context of Source Plants

Hyperoside as an isolated compound has not been the subject of formal pharmacokinetic drug interaction studies in humans. Its primary source plant, Hypericum perforatum (St. John's Wort), carries a well-documented profile of drug interactions through induction of cytochrome P450 enzymes (CYP3A4) and P-glycoprotein, primarily attributable to the constituent hyperforin rather than to hyperoside itself. Pretreatment with ethanolic extract of H. perforatum potentiated the hypnotic effect of pentobarbital and the impairment of motor coordination caused by diazepam to the greatest extent and also increased the paracetamol plasma concentration in comparison to the control group. These results were in correlation to naphtodianthrone concentrations. Therefore, drug interaction signals detected from whole Hypericum extract studies should not be attributed specifically to hyperoside without further evidence.

8.6 Limitations of Current Safety Evidence

The entire toxicological database for hyperoside as an isolated compound remains very thin. All formal toxicological studies have been conducted in animals only. No systematic human safety studies, pharmacovigilance data, or long-term human exposure studies for isolated hyperoside are available in the peer-reviewed literature. At present, few studies have explored the pharmacokinetics, especially the excretion, of hyperoside. Given renal accumulation and the early-stage developmental toxicology finding, further dedicated safety characterization in humans is warranted before isolated hyperoside supplements are widely used.

9. Current Research Gaps and Future Perspectives

This body of research aims to provide a comprehensive overview of hyperoside on its sources and biological activities to provide insights into its therapeutic potential, and to provide a basis for high-quality studies to determine the clinical efficacy of this compound. The overarching limitation across all areas of hyperoside pharmacology is the near-total absence of controlled human clinical trials evaluating hyperoside as an isolated entity. The bulk of mechanistic and efficacy data derives from in vitro experiments and rodent models, which frequently do not translate directly to human therapeutic outcomes.

Compared to traditional antidepressants targeting specific neurotransmitters, hyperoside appears to act through multiple mechanisms, potentially offering a broader therapeutic approach for depression. Further research elucidating the relative contributions of each mechanism could reveal hyperoside's potential for addressing different subtypes of depression or reducing side effects associated with single-target drugs.

Nanoparticle delivery systems (such as zein–tea polyphenol–pectin ternary complex nanoparticles) have been investigated as effective delivery systems for hyperoside, and such systems undoubtedly greatly improve the bioavailability of hyperoside, representing one avenue for improving clinical translatability.

References

• Wang et al. (2022). Hyperoside: A Review of Its Structure, Synthesis, Pharmacology, Pharmacokinetics and Toxicity. Molecules, 27(9), 3009. PMC9101560.
• Wang et al. (2023). Potential Implications of Hyperoside on Oxidative Stress-Induced Human Diseases: A Comprehensive Review. Journal of Inflammation Research. PMC10581022.
• Zhao et al. (2025). The multiple biological activities of hyperoside: from molecular mechanisms to therapeutic perspectives in neoplastic and non-neoplastic diseases. Frontiers in Pharmacology, 16, 1538601.
• Zhang et al. (2022). Hyperoside: A review on its sources, biological activities, and molecular mechanisms. Phytotherapy Research.
• Hyperoside: A Review of Resources, Synthesis Pathways, Physicochemical Properties, Metabolism, Pharmacological Activities, Clinical Trials and Human Studies, Toxicology and Safety, Marketed Products, and Patents. Springer Nature.
• Li et al. (2020). Hyperoside Induces Breast Cancer Cells Apoptosis via ROS-Mediated NF-κB Signaling Pathway. PMC6981893.
• Shi et al. (2016). Dietary Flavonoid Hyperoside Induces Apoptosis of Activated Human LX-2 Hepatic Stellate Cell by Suppressing Canonical NF-κB Signaling. PubMed 27110557.
• Zhang et al. (2023). Hyperoside alleviates toxicity of β-amyloid via endoplasmic reticulum-mitochondrial calcium signal transduction cascade in APP/PS1 double transgenic Alzheimer's disease mice. PMC9975698.
• Zhou et al. (2019). Suppression of 6-Hydroxydopamine-Induced Oxidative Stress by Hyperoside Via Activation of Nrf2/HO-1 Signaling in Dopaminergic Neurons. PMC6929192.
• Deng et al. (2024). Pharmacological activities and therapeutic potential of Hyperoside in the treatment of Alzheimer's and Parkinson's diseases: A systemic review. Neuroscience. ScienceDirect.
• Hyperoside: a multifaceted approach to cardiac protection. European Journal of Preventive Cardiology, 2025.
• Hou et al. (2017). Hyperoside protects against hypoxia/reoxygenation induced injury in cardiomyocytes by suppressing the Bnip3 expression. ScienceDirect.
• Yang et al. (2023). Exploring the role and mechanism of hyperoside against cardiomyocyte injury in mice with myocardial infarction based on JAK2/STAT3 signaling pathway. ScienceDirect.
• Song et al. (2022). The Role and Mechanism of Hyperoside against Depression-like Behavior in Mice via the NLRP1 Inflammasome. PMC9788057.
• Flavonoids against depression: a comprehensive review of literature. Frontiers in Pharmacology, 2024.
• Procognitive, Anxiolytic, and Antidepressant-like Properties of Hyperoside and Protocatechuic Acid Corresponding with the Increase in Serum Serotonin Level after Prolonged Treatment in Mice. PMC10747003.
• Hypericum perforatum (St John's wort) beyond depression: A therapeutic perspective for pain conditions. ScienceDirect, 2017.
• Hyperoside – an overview. ScienceDirect Topics (Biochemistry).
• Hyperoside – an overview. ScienceDirect Topics (Agricultural and Biological Sciences).
• Influence of different Hypericum perforatum L. preparations on pharmacokinetic and pharmacodynamic properties of pentobarbital, diazepam and paracetamol. PMC3506273.